I added a couple comments in the recent cliff note post from patients. I put it below.
As far as doctor, Lalezari has treat the most on mono. He has participated in many trials going back 20 years. He is also PI for mono.
He was in one CC last year and talked about mono and the patients, full transcript is here.
https://m.investorshangout.com/post/view?id=5516266
But patient talk
13:17 we could enroll the full study but it is
13:19 certainly true that in San Francisco we
13:21 it's been an easy sell
13:23 to offer patients once a week cept once
13:26 a week therapy I think that's what
13:27 everyone needs to sort of how to frame
13:30 this it's not sub-q it's it's once a
13:33 week and there are a lot of reasons why
13:34 people want to switch from daily oral
13:37 therapy to once a week therapy some of
13:40 its side effects some of its pill
13:42 fatigue some of its chaotic lifestyles
13:45 but it's not all patients but it is a
13:48 solid ten to fifteen percent of the
13:50 population and I think we'd probably
13:52 enrolled 150 patients now
14:46 the what I could contribute to this
14:48 conversation is just the observation
14:50 that the patients who do well on leronlimab
14:54 mono therapy love it and
14:57 whatever reason drove them into the
15:00 study obviously they got what they
15:02 wanted and then when it works are quite
15:04 happy but it's been a life changer for
15:08 patients that we have some of them have
15:10 been on this mono therapy now for five
15:12 years or more we don't see any concern
15:17 around injection site reactions I don't
15:20 see any at
15:21 all really safety or toxicity which is
15:24 partly why I'm excited about the breast
15:26 cancer study because if it works there
15:28 it's going to contribute some benefit
15:31 without adding any additional toxicity
15:34 or other issues so the patients do well
15:37 on leronlimab is mono therapy for HIV
15:39 love it
Also Sacha talking about PrEP need for weekly dosing, not daily pills for adherence.
05:40 so adherence the current regimens which
05:42 currently are daily oral antiretroviral
05:45 drugs and the uptake of those regimens
05:47 are the most critical barriers to ruling
05:49 out prep worldwide according to surveys
05:52 of high-risk individuals of men who have
05:54 sex with men approximately 25% of them
05:57 cite the inability to take oral
05:59 antiretroviral drugs daily as a reason
06:01 for their failure to adhere to the
06:02 regimens so the individuals that are at
06:05 high risk of HIV acquisitions are want
06:09 long-acting which we define as once a
06:12 week our greater prep agents and
06:14 currently their dose of leronlimab
06:16 which is once weekly subcutaneous
06:18 administration would fill a major gap in
06:20 prep we also believe that we can extend
06:22 this to further than once once weekly
06:25 the science really
https://www.poz.com/article/ccr5blocking-anti...n/comments
As far as doctor, Lalezari has treat the most on mono. He has participated in many trials going back 20 years. He is also PI for mono.
He was in one CC last year and talked about mono and the patients, full transcript is here.
https://m.investorshangout.com/post/view?id=5516266
But patient talk
13:17 we could enroll the full study but it is
13:19 certainly true that in San Francisco we
13:21 it's been an easy sell
13:23 to offer patients once a week cept once
13:26 a week therapy I think that's what
13:27 everyone needs to sort of how to frame
13:30 this it's not sub-q it's it's once a
13:33 week and there are a lot of reasons why
13:34 people want to switch from daily oral
13:37 therapy to once a week therapy some of
13:40 its side effects some of its pill
13:42 fatigue some of its chaotic lifestyles
13:45 but it's not all patients but it is a
13:48 solid ten to fifteen percent of the
13:50 population and I think we'd probably
13:52 enrolled 150 patients now
14:46 the what I could contribute to this
14:48 conversation is just the observation
14:50 that the patients who do well on leronlimab
14:54 mono therapy love it and
14:57 whatever reason drove them into the
15:00 study obviously they got what they
15:02 wanted and then when it works are quite
15:04 happy but it's been a life changer for
15:08 patients that we have some of them have
15:10 been on this mono therapy now for five
15:12 years or more we don't see any concern
15:17 around injection site reactions I don't
15:20 see any at
15:21 all really safety or toxicity which is
15:24 partly why I'm excited about the breast
15:26 cancer study because if it works there
15:28 it's going to contribute some benefit
15:31 without adding any additional toxicity
15:34 or other issues so the patients do well
15:37 on leronlimab is mono therapy for HIV
15:39 love it
Also Sacha talking about PrEP need for weekly dosing, not daily pills for adherence.
05:40 so adherence the current regimens which
05:42 currently are daily oral antiretroviral
05:45 drugs and the uptake of those regimens
05:47 are the most critical barriers to ruling
05:49 out prep worldwide according to surveys
05:52 of high-risk individuals of men who have
05:54 sex with men approximately 25% of them
05:57 cite the inability to take oral
05:59 antiretroviral drugs daily as a reason
06:01 for their failure to adhere to the
06:02 regimens so the individuals that are at
06:05 high risk of HIV acquisitions are want
06:09 long-acting which we define as once a
06:12 week our greater prep agents and
06:14 currently their dose of leronlimab
06:16 which is once weekly subcutaneous
06:18 administration would fill a major gap in
06:20 prep we also believe that we can extend
06:22 this to further than once once weekly
06:25 the science really
https://www.poz.com/article/ccr5blocking-anti...n/comments
1
